Filing Analysis
FibroBiologics, Inc. announced the appointment of Leigh Steinberg to its Board of Directors as a Class II director, effective August 20, 2026.
📋 Key Facts
- Leigh Steinberg appointed as Class II director effective August 20, 2026.
- Term to expire at the 2028 annual meeting of stockholders.
- Compensation will be consistent with the Company’s Non-Employee Director Compensation Policy.
- The Company entered into a standard form of indemnification agreement with Mr. Steinberg.
FibroBiologics, Inc. received a Staff Determination letter from Nasdaq notifying the company of its intention to delist its securities due to failure to maintain a minimum bid price of $1.00. The company is ineligible for the standard 180-day compliance period because it executed a reverse stock split within the prior year.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to maintain minimum bid price requirement (Rule 5550(a)(2))
- Ineligibility for compliance period due to recent reverse stock split (Red flag escalator)
- Imminent suspension of trading on July 31, 2026
📋 Key Facts
- Nasdaq Staff determined the Company's securities closed below $1.00 per share for 30 consecutive business days (June 8, 2026 - July 21, 2026).
- The company is ineligible for a 180-day compliance period due to a reverse stock split within the last year.
- Delisting and suspension are scheduled for the opening of business on July 31, 2026, unless an appeal is requested by July 29, 2026.
- The Company intends to request a hearing before a Nasdaq Hearings Panel to stay the delisting.
FibroBiologics, Inc. announced a change in its Board of Directors involving the resignation of Matt Link and the appointment of Kathleen Rubins, Ph.D., effective July 2 and July 8, 2026, respectively.
🚩 Red Flags
- Resignation of a director (Matt Link), though no specific reason for departure was provided in the filing.
📋 Key Facts
- Matt Link resigned from the Board of Directors effective July 2, 2026.
- Kathleen Rubins, Ph.D., appointed as a Class III director effective July 8, 2026.
- Dr. Rubins will serve on the Audit, Compensation, and Governance and Nominating Committees.
- Dr. Rubins' term expires at the 2029 annual meeting of stockholders.
- Dr. Rubins brings significant expertise from NASA (Astronaut) and academia (University of Pittsburgh).
- The appointment includes a standard indemnification agreement.
FibroBiologics, Inc. entered into a $3 million private placement agreement involving pre-funded warrants and various other warrants to an accredited investor. The offering includes significant potential dilution through the issuance of over 12 million total shares upon exercise of all warrant types.
🚩 Red Flags
- Significant potential dilution: Total maximum shares issuable via warrants and pre-funded warrants exceeds 12.5 million shares.
- Warrant pricing ($0.735) is likely significantly below current market value (implied by the use of pre-funded warrants to avoid >9.99% ownership thresholds).
- The company's need for $3M in working capital suggests immediate liquidity requirements.
📋 Key Facts
- Gross proceeds from the Offering: $3,000,000; Net proceeds: approximately $2.6 million.
- The offering includes Pre-Funded Warrants to purchase up to 4,081,633 shares of Common Stock at an exercise price of $0.00001 per share.
- Short-term and Long-term warrants were issued to the purchaser for a total of 8,163,266 shares at an exercise price of $0.735 per share.
- Placement Agent (H.C. Wainwright & Co., LLC) received a 7.0% cash fee and a 1.0% management fee, plus warrants for 285,714 shares.
- The issuance of warrant shares is subject to stockholder approval.
- A Registration Rights Agreement was signed requiring the company to file a registration statement within 15 days.
FibroBiologics, Inc. held its 2026 Annual Meeting of Stockholders on June 22, 2026, where shareholders approved a new equity incentive plan and the ratification of their independent auditor. The meeting also included the election of a new director and approval for share issuances related to outstanding warrants.
🚩 Red Flags
- Significant dilution potential: Approval of over 2.4 million shares related to warrant exercises and new equity plan authorizations.
📋 Key Facts
- Shareholders approved the FibroBiologics, Inc. 2026 Equity and Incentive Compensation Plan, which succeeds the 2022 Plan.
- The 2026 Plan provides for up to 2,000,000 new shares of common stock for issuance under incentive stock options.
- Pete O’Heeron was elected as a Class III director to serve until the 2029 Annual Meeting.
- WithumSmith+Brown, PC was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Shareholders approved the issuance of up to 2,272,728 shares upon exercise of warrants from March 2026 SPAs and up to 159,091 shares from an H.C. Wainwright & Co., LLC engagement letter.
- Stacy Coen's term as a Class III director expired at the conclusion of the meeting.
FibroBiologics, Inc. has increased the maximum aggregate offering price of its At The Market (ATM) offering to $7.5 million. The company is selling shares through H.C. Wainwright & Co., LLC and reported that 71,830 shares have already been sold under the agreement.
🚩 Red Flags
- Potential for ongoing shareholder dilution as the company sells shares 'at the market'.
- Reliance on ATM offerings for capital can indicate a lack of traditional institutional financing options for a micro-cap company.
📋 Key Facts
- The company filed an Updated ATM Prospectus Supplement on May 5, 2026, to increase the offering capacity to $7,500,000.
- The Sales Agent for the ATM offering is H.C. Wainwright & Co., LLC.
- As of the filing date, 71,830 shares of common stock have already been sold under the Sales Agreement.
- The offering utilizes the company's shelf registration statement on Form S-3 (No. 333-284663) which became effective on February 10, 2025.
FibroBiologics, Inc. granted stock options to its core executive team, including the CEO, CFO, CSO, and General Counsel, under the company's 2022 Stock Plan.
📋 Key Facts
- Grant date: May 4, 2026
- CEO Pete O'Heeron received options for 92,410 shares
- CFO Jason D. Davis, CSO Hamid Khoja, and GC Ruben A. Garcia each received options for 61,607 shares
- Exercise price for all options is $1.38 per share
- Vesting schedule: 25% after one year, followed by 36 equal monthly installments (4-year total vesting)
FibroBiologics, Inc. has entered into an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC to sell up to $6.15 million of its common stock. The company intends to use the proceeds for working capital and general corporate purposes.
🚩 Red Flags
- Potential dilution of existing shareholders through the issuance of up to $6.15 million in new equity.
📋 Key Facts
- Entered into an ATM agreement on May 1, 2026, with H.C. Wainwright & Co., LLC.
- Maximum aggregate offering price of $6,150,000.
- Sales agent receives a 3.0% commission on gross proceeds.
- Company to reimburse agent for $100,000 in legal fees and ongoing due diligence costs ranging from $3,500 to $5,000 per update.
- Shares will be issued under an existing S-3 shelf registration statement (No. 333-284663) effective since February 10, 2025.
FibroBiologics has regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements, closing previously disclosed listing matters. However, the company is now subject to a Mandatory Panel Monitor for one year, which eliminates standard cure periods for future non-compliance.
🚩 Red Flags
- Mandatory Panel Monitor status indicates a history of significant listing non-compliance.
- Loss of standard cure periods for the next 12 months increases the risk of sudden delisting.
- The company previously struggled with both minimum bid price and stockholders' equity simultaneously.
📋 Key Facts
- Confirmed compliance with Nasdaq Bid Price Rule 5550(a)(2) on April 17, 2026.
- Confirmed compliance with Nasdaq Stockholders' Equity Rule 5550(b)(1) on March 9, 2026.
- Placed under a Mandatory Panel Monitor for one year for both bid price and equity requirements.
- Any failure to maintain compliance during the monitor period will result in an immediate delist determination without a cure period.
FibroBiologics, Inc. amended its bylaws to significantly reduce the quorum requirement for stockholder meetings from a majority of voting power to just one-third.
🚩 Red Flags
- Lowering quorum requirements to one-third allows corporate actions to be approved by a smaller minority of shareholders, potentially reducing oversight.
- Such changes often indicate the company has had difficulty achieving a majority quorum in the past or anticipates difficulty passing upcoming proposals.
📋 Key Facts
- On April 16, 2026, the Board of Directors approved an amendment to Section 2.07 of the Company’s Amended and Restated Bylaws.
- The quorum requirement for stockholder meetings was lowered from a majority (over 50%) to one-third (33.3%) of the voting power.
- The amendment was effective immediately as of the Board's approval date.
FibroBiologics entered into a Sublease Buyout Agreement to terminate its lease at a Webster, Texas facility effective April 2, 2026. The company paid a one-time fee of $45,108.25 to exit the lease early, consolidating operations into its own laboratory facility.
📋 Key Facts
- Sublease terminated effective April 2, 2026, ahead of the original November 30, 2027 expiration date.
- One-time payment of $45,108.25 made to resolve remaining rent obligations.
- Estimated future rent savings of approximately $0.8 million.
- Company has relocated principal executive offices to 9350 Kirby Drive, Suite 300, Houston, Texas 77054.
FibroBiologics, Inc. entered into a Sublease Buyout Agreement to terminate its office lease in Webster, Texas, effective April 2, 2026, approximately 18 months ahead of schedule. The company paid $45,108.25 to exit the lease and expects to save approximately $0.8 million in future rent payments by consolidating operations into its new Houston facility.
📋 Key Facts
- Terminated sublease with United Fire & Casualty Co. effective April 2, 2026.
- The original sublease expiration date was November 30, 2027.
- A one-time buyout payment of $45,108.25 was made to resolve remaining rent obligations.
- The company expects to save approximately $0.8 million in future rent payments.
- Operations are being consolidated into a 10,000 square foot laboratory facility opened in 2025.
- The principal executive office address changed to 9350 Kirby Drive, Suite 300, Houston, Texas 77054.
FibroBiologics, Inc. implemented a 1-for-20 reverse stock split effective March 30, 2026. The split consolidated every twenty shares of common stock into one share, resulting in a change to the CUSIP number but maintaining the same trading symbol.
🚩 Red Flags
- Significant 1-for-20 reverse split ratio often indicates a struggle to maintain minimum bid price requirements for Nasdaq listing.
- Authorized shares were not reduced in proportion to the split, which significantly increases the potential for future equity dilution.
📋 Key Facts
- Reverse stock split ratio of 1-for-20 effective March 30, 2026.
- Fractional shares are rounded up to the nearest whole share.
- The CUSIP number for the Common Stock changed to 31573L204.
- The authorized number of shares of Common Stock remained unchanged despite the split.
- The par value of the Common Stock remains $0.00001 per share.
FibroBiologics, Inc. closed a best-efforts public offering on April 2, 2026, generating approximately $2.5 million in net proceeds. The offering involved the sale of common stock and pre-funded warrants, each bundled with a common warrant, with the exercisability of the common warrants contingent upon future stockholder approval.
🚩 Red Flags
- The 'best-efforts' nature of the offering suggests a lack of firm commitment from underwriters.
- Highly dilutive structure with 100% warrant coverage (one warrant for every share/pre-funded warrant sold).
- Exercisability of warrants is contingent on stockholder approval, indicating potential regulatory or authorized share hurdles.
- Small net raise of $2.5 million for a public company suggests a high burn rate or urgent liquidity needs.
- Restriction on 'Variable Rate Transactions' for one year suggests a history of or attempt to avoid 'death spiral' financing.
📋 Key Facts
- The offering consisted of 1,028,788 shares of common stock and 1,243,940 pre-funded warrants.
- The combined offering price was $1.32 per share and accompanying warrant.
- Net proceeds were approximately $2.5 million after fees and expenses.
- Common warrants have an exercise price of $1.32 but cannot be exercised until stockholder approval is obtained.
- H.C. Wainwright & Co., LLC served as the placement agent, receiving an 8% total fee and placement agent warrants for 159,091 shares.
- Executive officers and directors are subject to a 30-day lock-up period following the closing.
FibroBiologics, Inc. announced a base salary increase for its Chief Financial Officer, Jason D. Davis, to $400,000 effective January 1, 2026. The executive's target bonus remains at 40% of his base salary.
📋 Key Facts
- CFO Jason D. Davis's annual base salary increased to $400,000.
- The salary adjustment is retroactive to an effective date of January 1, 2026.
- Target non-equity incentive compensation remains unchanged at 40% of base salary.
- The change was approved by the Compensation Committee on March 4, 2026.
FibroBiologics, Inc. (FBLG) held a Special Meeting of Stockholders on February 20, 2026, at which shareholders approved five proposals including a reverse stock split at a ratio of 1-for-5 to 1-for-30 (exact ratio at Board's discretion), as well as Nasdaq Rule 5635(d) approvals for the issuance of shares underlying warrants from three separate Securities Purchase Agreements executed in November and December 2025. The combination of a pending reverse split and multiple rounds of warrant-based dilutive financing signals significant financial stress for this clinical-stage biologic company. All five proposals passed with strong majorities (~97% of votes cast in favor).
🚩 Red Flags
- Reverse stock split authorized at an aggressive range of up to 1-for-30, strongly suggesting the stock price has fallen or is at risk of falling below Nasdaq's $1.00 minimum bid price requirement
- Three separate Securities Purchase Agreements executed in rapid succession (Nov 18, Nov 24, and Dec 14, 2025) indicates urgent, repeated capital raises over a compressed ~4-week period
- Aggregate potential dilution of ~22.5 million new shares from warrant exercises against a current share base of ~99 million shares (~22.7% dilution)
- Nasdaq Rule 5635(d) shareholder approval required for all three financing tranches, confirming each was a below-market or discounted private placement
- H.C. Wainwright & Co. LLC received warrants as placement agent compensation across multiple deals, adding additional dilution on top of investor warrants
- Board granted unilateral discretion to set split ratio and timing without further stockholder input, concentrating significant decision-making power
📋 Key Facts
- Special Meeting held February 20, 2026; 54,974,113 of 99,019,722 eligible votes represented (~55.5% quorum)
- Proposal 1 APPROVED: Reverse stock split authorized at ratio of 1-for-5 to 1-for-30, exact ratio set at Board's discretion, effective within one year of stockholder approval (by ~Feb 20, 2027)
- Proposal 2 APPROVED: Issuance of up to 12,110,203 shares upon exercise of warrants from Securities Purchase Agreement dated November 18, 2025
- Proposal 3 APPROVED: Issuance of up to 4,477,614 shares from warrants per Securities Purchase Agreements dated November 24, 2025, plus 313,433 shares for H.C. Wainwright & Co. LLC engagement letter warrants
- Proposal 4 APPROVED: Issuance of up to 5,227,275 shares from warrants per Securities Purchase Agreements dated December 14, 2025, plus 365,909 shares for H.C. Wainwright & Co. LLC engagement letter warrants
- Proposal 5 APPROVED: Adjournment authority granted to Board if needed
- Total potential dilutive shares from warrant issuances: approximately 22,494,434 shares
- Record date for Special Meeting: December 26, 2025
- Filing signed by CEO Pete O'Heeron on February 23, 2026
- FBLG is an emerging growth company listed on Nasdaq; common stock par value $0.00001
FibroBiologics, Inc. received formal notice from Nasdaq that its failure to meet the Market Value of Listed Securities (MVLS) threshold serves as additional grounds for delisting. The company is currently awaiting a decision from the Nasdaq Hearings Panel regarding its request for continued listing.
🚩 Red Flags
- Delisting notice received from Nasdaq.
- Failure to meet Market Value of Listed Securities (MVLS) requirement.
- Existing deficiency regarding the Bid Price Rule.
- Proposed reverse stock split (1:5 to 1:30 ratio) to attempt compliance.
📋 Key Facts
- The Company failed to regain compliance with the MVLS Rule ($35 million minimum threshold) by the February 2, 2026 deadline.
- Nasdaq issued formal notice on February 3, 2026, stating non-compliance is an additional basis for delisting.
- The company is already in deficiency regarding the Bid Price Rule (Listing Rule 5550(a)(2)).
- A shareholder vote is pending to approve a reverse stock split with a ratio between 1:5 and 1:30 to address compliance issues.
FibroBiologics, Inc. received a second notification from Nasdaq stating plans to delist its securities due to failure to regain compliance with the $1.00 minimum bid price requirement by the December 29, 2025 deadline. The company intends to request a hearing before the Nasdaq Hearings Panel to stay the delisting action and is proposing a reverse stock split to restore compliance.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to meet minimum bid price requirement ($1.00)
- Proposed reverse stock split (ratio up to 1-for-30)
📋 Key Facts
- Nasdaq notified the company on December 30, 2025, of plans to delist due to continued non-compliance with Rule 5550(a)(2).
- The company failed to meet the $1.00 minimum bid price requirement by the end of the 180-day compliance period (December 29, 2025).
- The company plans to request a hearing before the Nasdaq Hearings Panel to stay delisting.
- Definitive proxy materials were filed on December 29, 2025, proposing a reverse stock split with a ratio between 1-for-5 and 1-for-30.
FibroBiologics, Inc. announced a registered direct offering and concurrent private placement of 5,227,275 shares at $0.33 per share to raise approximately $1.7 million in gross proceeds. The deal includes warrants for the same number of shares, which require stockholder approval.
🚩 Red Flags
- Significant dilution: The offering includes warrants for 100% of the shares being sold, potentially doubling the share count upon exercise.
- Low share price: Offering price of $0.33 per share suggests a highly distressed valuation or potential delisting risk context.
- Warrant dependency: Issuance is subject to stockholder approval and Nasdaq compliance rules regarding beneficial ownership/voting.
- Cash burn indicator: The company is raising a relatively small amount ($1.7M) for 'working capital,' suggesting limited runway.
📋 Key Facts
- Registered direct offering of 5,227,275 common shares at $0.33 per share.
- Concurrent private placement of 5,227,275 warrants to purchase common stock at $0.33 per share.
- Expected gross proceeds from the equity sale: ~$1.7 million; potential additional $1.7 million if warrants are exercised for cash.
- H.C. Wainwright & Co., LLC is acting as the exclusive placement agent with an 8% total fee (7% cash, 1% management).
- The offering includes a 15-day standby period on issuing new equity and a one-year prohibition on Variable Rate Transactions.
- CEO Pete O’Heeron entered into a voting agreement to support the issuance of warrant shares for Nasdaq compliance.
FibroBiologics, Inc. announced a registered direct offering and concurrent private placement of 4,477,614 shares at $0.335 per share, alongside warrants to purchase an equal number of shares. The company intends to use the approximately $1.5 million in gross proceeds for working capital and general corporate purposes.
🚩 Red Flags
- Significant dilution: The issuance of warrants equal to the number of shares offered creates substantial potential for future dilution.
- Low share price: Offering price of $0.335 suggests a highly distressed or low-priced micro-cap environment.
- Small capital raise: Total gross proceeds of $1.5 million is relatively small, suggesting limited runway even with the infusion.
📋 Key Facts
- Registered direct offering of 4,477,614 common shares at $0.335 per share.
- Concurrent private placement of warrants to purchase 4,477,614 shares at an exercise price of $0.335.
- Expected gross proceeds from the offering: ~$1.5 million; potential additional $1.5 million if warrants are exercised for cash.
- H.C. Wainwright & Co., LLC acting as exclusive placement agent with a 7% cash fee and 1% management fee.
- Placement Agent Warrants issued to H.C. Wainwright for up to 313,433 shares at an exercise price of $0.4188.
- The offering is being conducted under the company's existing Form S-3 registration statement (effective Feb 10, 2025).
- Warrants are subject to stockholder approval and include a 4.99% beneficial ownership limitation.
FibroBiologics, Inc. entered into a registered direct offering and concurrent private placement to issue common stock and warrants to a single investor. Notably, the consideration for the securities is not cash but sovereign-issued fine gold coins valued at $4,069.18 per oz.
🚩 Red Flags
- Highly unusual consideration (physical gold coins) introduces significant valuation, operational, and liquidity risks.
- Extreme dilution potential: The issuance of warrants could result in up to 12.1 million additional shares being issued.
- Pre-funded warrants with an exercise price of $0.00001 essentially function as immediate equity issuance upon closing.
- Complexity in liquidation: Company must convert gold to USD, exposing them to gold price volatility and physical handling/storage risks.
📋 Key Facts
- Registered Direct Offering: 3,540,000 shares of common stock and pre-funded warrants to purchase up to 8,570,203 shares.
- Price per Share/Pre-Funded Warrant: $0.3303 (approximate).
- Warrants: Issuance of warrants to purchase one share for each share/pre-funded warrant purchased; total potential shares: 12,110,203.
- Consideration: Payment via sovereign-issued .9999 fine gold coins instead of cash.
- Gross Proceeds: Expected ~$4.0 million from the direct offering; additional ~$4.0 million if warrants are exercised for cash.
- Use of Proceeds: General corporate purposes, including debt satisfaction.
FibroBiologics, Inc. received a notification from Nasdaq stating it has failed to meet the minimum Market Value of Listed Securities (MVLS) requirement of $35.0 million. The company has 180 days to regain compliance before facing potential delisting.
🚩 Red Flags
- Failure to meet minimum market value requirements (MVLS) is a precursor to delisting.
- Potential for significant downward pressure on stock price if compliance is not met by February 2, 2026.
- Risk of being relegated to over-the-counter (OTC) markets if the delisting process proceeds.
📋 Key Facts
- Received notice on August 4, 2025, regarding non-compliance with Nasdaq Listing Rule 5550(b)(2).
- The company failed to maintain a minimum MVLS of $35.0 million.
- Compliance period: 180 calendar days, expiring February 2, 2026.
- To regain compliance, the MVLS must close at $35.0 million or more for ten consecutive business days before the deadline.
FibroBiologics, Inc. filed an amendment to its previous 8-K to disclose the specific share counts associated with a $15 million Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. The filing details potential significant dilution through convertible promissory notes and equity commitments.
🚩 Red Flags
- Significant potential dilution: The conversion price of $0.406 per share for the promissory notes suggests a highly discounted rate compared to the SEPA commitment price of $2.26.
- Use of SEPA (Standby Equity Purchase Agreement): This is often used by micro-cap companies facing liquidity constraints, frequently resulting in heavy dilution for existing shareholders.
📋 Key Facts
- The company entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. on December 20, 2024.
- The total principal amount of the Promissory Notes is $15.0 million, to be advanced in three tranches.
- Conversion of the $15.0 million in notes could result in the issuance of up to 36,945,812 shares (assuming a conversion price of $0.406 per share).
- The SEPA includes a commitment amount that may result in the issuance of up to 4,424,778 shares (assuming a purchase price of $2.26).
- Total potential dilution from this agreement involves over 41 million shares.
FibroBiologics, Inc. reported multiple conversions of convertible promissory notes issued under a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. The filing details several equity issuances at varying discount prices between June and July 2025.
🚩 Red Flags
- Use of SEPA (Standby Equity Purchase Agreement) often indicates urgent need for liquidity and can lead to significant shareholder dilution.
- Downward trend in conversion prices: The most recent conversion on July 15, 2025, was at $0.5624, significantly lower than the June conversions (~$0.67), suggesting a declining share price or increasing investor leverage.
- High remaining debt load from convertible notes totaling $8.9 million (First and Third Notes).
📋 Key Facts
- The company is utilizing a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. (a Cayman Islands exempt limited company).
- Multiple notes were issued: First Note ($5M), Second Note ($5M), and Third Note ($5M).
- As of the filing date, the Second Note has been converted in full.
- The First Note has a remaining principal balance of $5.0 million.
- The Third Note has a remaining principal balance of $3.9 million.
- Conversions occurred at prices ranging from $0.6934 to $0.5624 per share.
FibroBiologics, Inc. received a notification from Nasdaq stating that its common stock has fallen below the minimum $1.00 closing bid price requirement for 30 consecutive trading days. The company has been granted an initial 180-day period to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq
- Stock price sustained below $1.00 (Penny stock territory)
- Potential for mandatory reverse stock split to regain compliance
📋 Key Facts
- Received Nasdaq notice on July 1, 2025, regarding a violation of Nasdaq Listing Rule 5550(a)(2).
- The deficiency is due to the closing bid price being below $1.00 for the last 30 consecutive trading days.
- The company has an initial compliance period until December 29, 2025.
- To regain compliance, the stock must close at $1.00 or more for at least 10 consecutive business days before the deadline.
- A second 180-day extension may be available if specific market value and listing standard requirements are met.
FibroBiologics, Inc. has completed the third and final $5 million tranche of a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., via a convertible promissory note. This follows several previous tranches that have resulted in significant equity dilution through multiple conversions at declining share prices.
🚩 Red Flags
- Heavy dilution: Multiple conversions listed show a consistent downward trend in share price (from $1.63 down to $0.67).
- Death Spiral characteristics: The conversion mechanism (94% of VWAP) and the declining conversion prices suggest significant dilutive pressure on existing shareholders.
- High default penalty: Interest rate jumps from 0% to 18% upon default, creating high pressure to meet maturity/extension terms.
📋 Key Facts
- Third Closing occurred on June 16, 2025, for $5 million principal amount.
- The Third Promissory Note matures on December 20, 2025, with optional extensions to early 2026 for a fee.
- Conversion price is the lower of $0.9801 or 94% of the five-day VWAP (subject to a floor).
- Interest rate is 0%, but jumps to 18% upon an Event of Default.
- The Investor has already converted significant portions of previous notes, with conversion prices dropping from $1.63 in January to as low as $0.67 in June 2025.
FibroBiologics, Inc. reported the results of its Annual Meeting of Stockholders held on June 12, 2025. The meeting included the election of directors and approval of an amendment to increase authorized capital stock.
🚩 Red Flags
- Approval of share issuance exceeding specific limits (Nasdaq Rule 5635(d)) suggests potential future dilution through standby equity agreements.
📋 Key Facts
- Annual Meeting held on June 12, 2025; 54,542,916 votes represented out of 70,498,943 total votes entitled to be cast.
- Matthew Link and Victoria Niklas, M.D. were elected as Class II directors (terms until 2028).
- Shareholders ratified the appointment of WithumSmith+Brown, PC as independent auditor for FY ending Dec 31, 2025.
- Shareholders approved an amendment to the Certificate of Incorporation to increase authorized capital stock.
- Shareholders approved a Nasdaq Listing Rule 5635(d) requirement allowing issuance of common stock to YA II PN, LTD. in excess of 7,013,635 shares via a Standby Equity Purchase Agreement.
FibroBiologics, Inc. announced the appointment of Jason D. Davis as Chief Financial Officer, effective June 9, 2025. The filing details his compensation package, including salary, bonuses, and stock options.
📋 Key Facts
- Jason D. Davis appointed as CFO effective June 9, 2025.
- Base salary set at $350,000 per annum.
- Eligible for an annual performance bonus of up to 40% of base salary.
- Granted 450,000 stock options under the 2022 Stock Plan with a 1-year cliff and monthly vesting thereafter.
- One-time cash commencement bonus of $15,000.
- Severance package includes nine months of base salary and COBRA premiums if terminated without cause or for good reason.
FibroBiologics, Inc. announced the voluntary resignation of its Interim Chief Financial Officer, Robert E. Hoffman, effective May 14, 2025. Mr. Hoffman will remain on the Company's Board of Directors as a Class I director.
🚩 Red Flags
- Departure of an Interim CFO can indicate potential instability in financial leadership or transition friction, though the voluntary nature and retention as a Director mitigates some risk.
📋 Key Facts
- Robert E. Hoffman is resigning from his role as Interim CFO.
- Resignation is voluntary and intended to pursue another opportunity.
- Effective date of departure from officer role: May 14, 2025.
- Mr. Hoffman will continue to serve on the Board of Directors (Class I director).
- The Company has initiated a search for a permanent successor.
FibroBiologics, Inc. reported multiple conversions of convertible promissory notes issued under a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. The filing details several tranches of equity issuance to satisfy commitment fees and convert principal amounts into common stock.
🚩 Red Flags
- Use of Standby Equity Purchase Agreement (SEPA) often indicates urgent need for liquidity/cash runway extension.
- Significant dilution via convertible notes with conversion prices significantly lower than the initial commitment fee price ($1.49 - $1.63 vs $2.10).
- Frequent equity issuance (multiple conversions in a single month) suggests high burn rate or immediate need for capital.
📋 Key Facts
- The company entered into a $15 million SEPA with YA II PN, LTD. on December 20, 2024.
- Two tranches of $5.0 million each were disbursed in late December 2024.
- On January 7, 2025, the company issued 118,991 shares at $2.1010/share to satisfy a $250,000 commitment fee.
- Multiple conversions of the 'Second Note' occurred in Jan/Feb 2025, with conversion prices ranging from $1.4955 to $1.6301 per share.
- The Second Note has a remaining principal balance of $2.0 million.
- Total shares issued across reported conversions: approximately 2,037,621 shares.
FibroBiologics, Inc. filed an 8-K to provide an updated Summary Compensation Table for its named executive officers following the determination of fiscal 2024 annual incentive bonuses.
🚩 Red Flags
- High level of equity-based compensation (option awards) relative to base salary for several executives.
📋 Key Facts
- The Board and Compensation Committee approved fiscal 2024 annual incentive bonuses for Named Executive Officers on January 23, 2025.
- CEO Pete O’Heeron received $1,805,199 in total compensation for FY2024, including $788,452 in option awards and $390,000 in non-equity incentive plan compensation.
- CSO Hamid Khoja, Ph.D. received $853,646 in total compensation for FY2024.
- General Counsel Ruben A. Garcia received $2,752,843 in total compensation for FY2024, largely driven by $2,283,274 in option awards.
- Interim CFO Robert E. Hoffman was approved a bonus of $75,000.
FibroBiologics, Inc. completed the second tranche of a $15 million Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., receiving a $5 million convertible promissory note on December 30, 2024. The filing also details new stock option grants for the CEO and Chief Scientific Officer.
🚩 Red Flags
- Use of a Standby Equity Purchase Agreement (SEPA) often indicates urgent need for liquidity and can lead to significant shareholder dilution.
- Convertible note includes a punitive interest rate hike (from 0% to 18%) in the event of default.
- Conversion price is tied to a discount of the VWAP, which typically results in downward pressure on the stock price as shares are issued.
📋 Key Facts
- Second tranche of SEPA disbursed on December 30, 2024, in the amount of $5 million.
- The $5 million is evidenced by a convertible promissory note maturing on December 20, 2025.
- Interest rate is 0% currently, but increases to 18% upon an Event of Default.
- Conversion price for the note is the lower of $2.84 per share or 94% of the 5-day VWAP (subject to a floor price).
- CEO Pete O’Heeron granted options for 406,339 shares at an exercise price of $2.36.
- CSO Hamid Khoja granted options for 176,200 shares at an exercise price of $2.36.
FibroBiologics entered into a $15 million Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., involving three tranches of convertible promissory notes. The agreement includes significant dilution terms and investor-friendly conversion features.
🚩 Red Flags
- Highly dilutive conversion terms (94% of VWAP or $2.41 floor).
- Significant interest rate penalty (18%) in the event of default.
- Investor-friendly 'Investor Notice' allows the investor to force share issuance at their discretion.
- Structuring and commitment fees totaling $275,000 paid via cash/shares.
📋 Key Facts
- Total Pre-Paid Advance amount: $15 million via three $5 million tranches.
- First tranche of $5 million was disbursed on December 20, 2024.
- Conversion price is the lower of $2.41 per share or 94% of the 5-day VWAP (subject to a floor).
- Investor has an option for a $10 million 'Commitment Amount' through December 20, 2026.
- Promissory notes carry 0% interest but jump to 18% upon an Event of Default.
- The agreement includes a 6% original issue discount (OID) on each tranche.
- Investor is limited to owning no more than 4.99% of outstanding shares.
FibroBiologics, Inc. has entered into a side letter with GEM Global Yield LLC to terminate its existing Share Purchase Agreement (SPA) and warrant through a final equity issuance. The transaction involves the sale of 1,152,074 shares at $2.17 per share to settle outstanding commitment fees.
🚩 Red Flags
- Use of 'death spiral' style financing: The company is issuing equity at a fixed price to settle debt/fees, which can lead to significant dilution.
- Termination of existing warrant and SPA via an immediate share issuance suggests urgent need for liquidity or restructuring of debt obligations.
📋 Key Facts
- Company issued 1,152,074 shares of common stock to GEM on December 19, 2024.
- Shares were sold at a fixed price of $2.17 per share for an aggregate amount of $2.5 million.
- The transaction includes a waiver of the remaining $1.5 million commitment fee previously owed under the GEM SPA.
- The existing warrant (issued Feb 14, 2024) for 1,299,783 shares has been terminated in full.
- The GEM SPA is scheduled to terminate effective December 20, 2024.
FibroBiologics, Inc. announced the voluntary resignation of its CFO, Mark Andersen, effective November 15, 2024 (or upon appointment of a successor). Robert Hoffman, a current Board member with extensive biotech finance experience, has been appointed as Interim CFO.
🚩 Red Flags
- Sudden departure of the Chief Financial Officer (CFO) can sometimes signal internal friction or disagreements regarding financial reporting/strategy, though no restatement was mentioned here.
- The company is undergoing leadership changes in both the CFO role and Audit/Compensation committees simultaneously.
📋 Key Facts
- CFO Mark Andersen is resigning to pursue other opportunities; resignation effective date is either when a successor starts or November 15, 2024.
- Interim CFO Robert Hoffman appointed effective October 30, 2024.
- Separation Agreement includes a transition period where Andersen will assist with knowledge transfer.
- If a General Release is signed, Andersen receives 9 months of base salary as transition payments and COBRA reimbursement.
- Robert Hoffman's monthly cash compensation as Interim CFO is $45,833.
FibroBiologics, Inc. entered into a Master Services Agreement (MSA) with Charles River Laboratories, Inc. (CRL) to secure development and manufacturing services. The agreement is set to expire in September 2029 unless terminated earlier.
📋 Key Facts
- Entered into a Master Services Agreement (MSA) with Charles River Laboratories, Inc. on September 19, 2024.
- The agreement governs development and manufacturing services via specific Statements of Work (SOW).
- The contract term expires on September 19, 2029.
- Termination requires a 90-day prior written notice by either party.
FibroBiologics, Inc. held its Annual Meeting of Stockholders on August 27, 2024, where shareholders approved a Capital Decrease Amendment and elected several directors. The filing also confirms the ratification of WithumSmith+Brown, PC as the independent auditor.
🚩 Red Flags
- Approval of a 'Capital Decrease Amendment' can sometimes be a precursor to or part of a restructuring/reverse split process to increase share price or meet exchange requirements, though the specific mechanics are not detailed in this summary filing.
📋 Key Facts
- Annual Meeting held on August 27, 2024; quorum represented 55,115,522 votes out of 68,219,125 total votes.
- Richard Cilento and Robert Hoffman elected as Class I directors to serve until the 2027 Annual Meeting.
- Shareholders approved Proposal 3: Capital Decrease Amendment to reduce authorized capital stock.
- Shareholders approved Proposal 4: Clarifying Amendment to eliminate obsolete provisions in the Certificate of Incorporation.
- WithumSmith+Brown, PC ratified as the independent registered public accounting firm for the fiscal year ending Dec 31, 2024.
FibroBiologics, Inc. completed a share sale of 100,000 common shares to GEM Global Yield LLC SCS at a net price of $4.51 per share. This transaction is part of an existing equity line agreement (GEM SPA) and represents continued use of the company's convertible/equity financing facility.
🚩 Red Flags
- Continued reliance on equity financing (GEM SPA) to generate cash flow.
- Use of discounted share sales can lead to shareholder dilution.
📋 Key Facts
- Sold 100,000 shares to GEM Global Yield LLC SCS on August 26, 2024.
- Shares sold at a net price of $4.51 per share (reflecting a 10% discount).
- Gross proceeds from this specific transaction: $451,000.
- Aggregate gross proceeds received from GEM under the GEM SPA subsequent to June 30, 2024, total $3,887,000.
- The sale was conducted via a draw down notice delivered on July 12, 2024.
FibroBiologics, Inc. has adopted amended and restated bylaws effective June 25, 2024. The changes primarily align the company's governing documents with recent SEC universal proxy rules and Delaware General Corporation Law updates.
🚩 Red Flags
- Increased threshold (66 2/3%) for stockholders to amend bylaws may reduce shareholder influence.
📋 Key Facts
- Board approved and adopted Amended and Restated Bylaws on June 25, 2024.
- Amendments address SEC universal proxy rules (Rule 14a-19) regarding proxy solicitation procedures.
- The threshold for stockholders to amend the Bylaws has been raised to 66 2/3%.
- Provisions allowing a majority of shares to remove directors with or without cause have been removed.
- Provisions regarding stockholder meetings and special meeting calls were updated to align with Delaware law.
FibroBiologics, Inc. filed a Form S-1 registration statement for a 'best efforts' public offering of units. The filing includes business updates and recent developments as part of the registration process.
🚩 Red Flags
- Public offering of units often indicates an immediate need for capital, which can lead to dilution for existing shareholders.
📋 Key Facts
- Filed a Form S-1 registration statement (File No. 333-278938) on April 26, 2024.
- The offering is described as a 'best efforts' public offering of units.
- The filing includes business updates and recent developments in Exhibit 99.1.
FibroBiologics, Inc. issued an 8-K to announce the presentation of preclinical and clinical data at the 2024 ACTRIMS Forum. The filing serves as a vehicle to incorporate their press release regarding scientific developments into the public record.
📋 Key Facts
- Company presented preclinical and clinical data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum.
- The announcement was made via press release on February 20, 2024.
- The filing is categorized under Item 8.01 (Other Events).
FibroBiologics, Inc. issued an 8-K to announce the presentation of preclinical data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases.
📋 Key Facts
- Event date: February 13, 2024
- Content: Presentation of preclinical data at a scientific symposium (Keystone Symposia)
- Exhibit 99.1 contains the full press release regarding the data presentation
FibroBiologics, Inc. issued a press release announcing the issuance of three United States patents related to its fibroblast technology.
📋 Key Facts
- Announced the issuance of three new U.S. patents on February 8, 2024.
- The patents pertain to the company's proprietary fibroblast technology.
- The announcement was made via a press release incorporated by reference as Exhibit 99.1.
FibroBiologics, Inc. announced the successful issuance of three patents by the Japan Patent Office (JPO). This filing serves to communicate intellectual property developments in a key international market.
📋 Key Facts
- Date of event: February 6, 2024
- The company received three new patents from the Japan Patent Office (JPO)
- Filing includes a press release as Exhibit 99.1 regarding the patent issuance
FibroBiologics, Inc. announced its direct listing on the Nasdaq Global Market under the ticker symbol FBLG, effective January 31, 2024.
📋 Key Facts
- Company completed a direct listing on the Nasdaq Global Market.
- Trading ticker symbol is FBLG.
- The event was reported via Item 8.01 (Other Events) on January 31, 2024.